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Abstract
Introduction: RAD21 is a component of the cohesin complex, which is essential for chromosome segregation and
error-free DNA repair. We assessed its prognostic and predictive power in a cohort of in situ and invasive breast
cancers, and its effect on chemosensitivity in vitro.
Methods: RAD21 immunohistochemistry was performed on 345 invasive and 60 pure in situ carcinomas.
Integrated genomic and transcriptomic analyses were performed on a further 48 grade 3 invasive cancers.
Chemosensitivity was assessed in breast cancer cell lines with an engineered spectrum of RAD21 expression.
Results: RAD21 expression correlated with early relapse in all patients (hazard ratio (HR) 1.74, 95% confidence
interval (CI) 1.06 to 2.86, P = 0.029). This was due to the effect of grade 3 tumors (but not grade 1 or 2) in which
RAD21 expression correlated with early relapse in luminal (P = 0.040), basal (P = 0.018) and HER2 (P = 0.039)
groups. In patients treated with chemotherapy, RAD21 expression was associated with shorter overall survival (P =
0.020). RAD21 mRNA expression correlated with DNA copy number, with amplification present in 32% (7/22) of
luminal, 31% (4/13) of basal and 22% (2/9) of HER2 grade 3 cancers. Variations in RAD21 mRNA expression in the
clinical samples were reflected in the gene expression data from 36 breast cancer cell lines. Knockdown of RAD21
in the MDA-MB-231 breast cancer cell line significantly enhanced sensitivity to cyclophosphamide, 5-fluorouracil
and etoposide. The findings for the former two drugs recapitulated the clinical findings.
Conclusions: RAD21 expression confers poor prognosis and resistance to chemotherapy in high grade luminal,
basal and HER2 breast cancers. RAD21 may be a novel therapeutic target.
Introduction
Cohesin is a multi-protein complex that is highly con-
served from yeast to humans. Its primary role is to
adhere sister chromatids in close apposition, a mechan-
ism termed ‘sister chromatid cohesion’ (SCC). SCC is
fundamental to several key cellular processes, including
chromosome segregation during mitosis and meiosis,
error-free homologous recombinational repair (HRR) of
DNA double strand breaks and the regulation of gene
transcription [1-7]. The core cohesin complex consists
of four proteins, RAD21 (also known as SCC1 or
MCD1), SMC1, SMC3 and SCC3 [8].
RAD21 is a central component of the cohesin com-
plex, both structurally and functionally [8]. Aberrant
RAD21 expression has been reported in multiple cancers
and cancer cell lines [9-12]. In a mega-scale microarray
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analysis of multiple cancers, RAD21 was identified as
one of 69 signature genes in undifferentiated cancers
that had aggressive in vitro or clinical courses and poor
patient outcomes [9]. Further, an intronal single nucleo-
tide polymorphism (SNP) in the RAD21 gene is strongly
associated with increased breast cancer risk [10].
Although these reports support the notion that the
abnormal activity of RAD21 may be an important fea-
ture of human breast cancer, there are no data available
from clinical breast cancer samples.
We therefore, evaluated RAD21 expression in a cohort
of well-characterised human in situ and invasive breast
cancers to 1) assess the correlation between RAD21
expression, and conventional and molecular clinico-
pathological parameters and patient prognostic data;
and 2) determine whether aberrant RAD21 expression
might predict therapeutic outcomes.
Materials and methods
Patient clinicopathological variables
The flow of patients through the study according to the
reporting recommendations for tumor marker prognos-
tic studies (REMARK) criteria [13] is listed in Additional
file 1. Four hundred and nine invasive cancers were
obtained from the Garvan Institute (292 cases with sur-
vival and treatment data) and the Peter MacCallum
Cancer Centre (117 cases without survival data). Sixty-
four cases were excluded due to lack of tissue available
for tissue microarray (TMA) construction or absence of
tumor on the array. The final cohort of invasive cancers
was 345 cases (251 cases with survival data). For ductal
carcinoma in situ (DCIS), 60 cases of pure DCIS were
obtained from the John Radcliffe Hospital, UK, and
were assessed on TMAs. This study has Ethics Commit-
tee approvals (numbers 00/81, 03/90, 09/36, JRC02.216,
HREC SVH H94/080 and HREC SVH 06336 H00036).
Patient median age was 54 years (range 24 to 87 years).
Forty-one percent of patients received adjuvant che-
motherapy with cyclophosphamide/methotrexate/5-
fluorouracil (CMF), or doxorubicin (adriamycin)/cyclo-
phosphamide (AC). Fifty-two percent received adjuvant
endocrine therapy with tamoxifen. Patient median fol-
low-up was 58.1 months. During this time, 100 patients
developed recurrence (24.4%) and 86 deaths (21.0%)
were considered breast-cancer related.
Immunohistochemistry
TMAs were constructed from 1 mm diameter (invasive
cancers) or 2 mm cores (DCIS). Sections of 4 μm thick-
ness were used for immunostaining using the EnVi-
sion™kit (DAKO, Glostrup, Denmark) following the
manufacturer’s instructions. Briefly, de-paraffinized and
rehydrated tissue sections were treated for antigen
retrieval in 10 mM Tris-HCl (pH 9.0) buffer containing
1 mM EDTA for three minutes at 125°C in a pressure
cooker (Biocare Decloker, Concord, CA, USA). Sections
were then treated with 3% H2O2 for five minutes to
remove endogenous peroxides, washed and incubated
with a rabbit polyclonal anti-RAD21 antibody (1:200)
(Abcam, Cambridge, UK), with anti-rabbit IgG as nega-
tive control, for two hours at room temperature. Horse-
radish peroxidase (HRP)-conjugated secondary antibody,
the signal was detected using DAB (3’, 3’-diaminobenzi-
dine) substrate. Sections were counter-stained with
hematoxylin to visualize nuclei. Validation of the anti-
RAD21 antibody was performed using small interference
RNA (siRNA) knockdown of the human RAD21 gene in
MCF10A cells on cell blocks (Additional file 2).
Nuclear RAD21 expression was assessed for intensity (0
= no staining, 1 = weak, 2 = moderate, 3 = strong) and
the percentage of positive cells (0 = 0%, 1 ≤10%, 2 = 10%
to 50%, 3 = 51% to 80%, 4 ≥80% positive cells) as defined
previously [14]. The scores for intensity and percentage
were added and a cut-off of 7 was used to define two
approximately equal size groups of patients for subse-
quent statistical analyses.
ER, HER2, EGFR and CK5/6 staining were used to
classify tumors into four intrinsic subgroups: the basal
group (ER negative, HER2 negative, CK5/6 and/or EGFR
positive), luminal group (ER positive, HER2 negative),
HER2 group (HER2 positive) and the negative (null)
group (ER, HER2, CK5/6 and EGFR negative) [15].
Cell lines
Cell lines (MCF7, MCF10A, MDA-MB-231, MDA-MB-
468, SK-BR-3, T47 D and ZR75-1) were obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA). MCF10A was grown and maintained in a 1:1 mix-
ture of Dulbecco’s modified Eagle medium (DMEM) F-12
supplemented with 5% horse serum, 20 ng of epidermal
growth factor (EGF) per ml, 10 μg/ml of insulin, and 0.5
μg/ml of hydrocortisone. MDA-MB-468, SK-BR-3 and
ZR75-1 were grown in MEM with 10% fetal bovine serum
(FBS) and 1% Pen/Strep. Other cell lines were grown in
RPMI-1640 with 10% FBS and 1% Pen/Strep. SVCT was
obtained from European Collection of Cell Cultures
(ECACC; Salisbury, Wilts, UK) and grown in DMEM with
10% FBS, 5 μg/ml hydrocortisone, and 10 μg/ml insulin.
Quantitative real time PCR and Semi-quantitative Western
blot analysis
Exponentially growing cells were harvested and total
RNA was extracted using RNeasy kits (Qiagen, Valencia,
CA, USA). DNA was removed by on-column treatment
with RNase-free DNase. One microgram of total RNA
was used for cDNA synthesis using a Superscript III kit
(Invitrogen, Carlsbad, CA, USA). cDNA was used for
quantitative real time polymerase chain reaction (qRT-
PCR) using primers (5’-AATTTGGCTAGCGGCCCAT-
3’ and 5’-TGTCCGTAATGCCATTTTCACC-3’) which
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span exon 10 and exon 11 of the human RAD21 gene.
Phosphoglycerate kinase (PGK) was used as a house-
keeping gene and the relative expression of RAD21 gene
was determined from three independent experiments
using the DeltaDelta CT method [16].
Total protein extraction and Western blots were carried
out essentially as described previously [17]. For Western
blot analysis, blots were incubated with a rabbit polyclonal
anti-RAD21 antibody (Abcam, Cambridge, UK) followed
by a fluorescence-conjugated secondary antibody, Alexa
680 anti-rabbit (Invitrogen, Carlsbad, CA, USA). The sig-
nal intensity was measured using the Li-Cor Odyssey sys-
tem. Membranes were then probed with a mouse
monoclonal anti-pan actin antibody (Cell Signaling Tech-
nology, Danvers, MA, USA) followed by an IRDye800-
conjugated anti-mouse antibody (Rockland, Gilbertsville,
PA, USA). The relative level of protein expression was
determined by normalizing to the pan-actin loading con-
trol from a minimum of three independent experiments.
Array CGH and gene expression analysis
Array comparative genomic hybridization (CGH) and
microarray-based expression profiling were obtained
from analysis of 48 microdissected grade 3 invasive duc-
tal carcinomas as described [18]. Tumor subtypes were
determined as described above [15].
Gene expression data mining
Gene expression profiles of 38 breast cancer cell lines were
obtained by mining a microarray dataset described by Hol-
lestelle et al. (2009) [19] at GEO (accession number (GEO:
GSE16795)) [20]. Raw intensity values of all samples were
normalized by RMA normalization (Robust Multichip
Analysis) (background correction and normalization)
using Partek version 6.4 (Partek Inc., St. Louis, MO). The
normalized data file was transposed, back transformed to
normal intensity values and imported into OmniViz ver-
sion 6.0.1 (BioWisdom Ltd., Cambridge, UK) for further
analysis. For each probe set, the geometric mean of the
hybridization intensity of all samples was calculated. The
level of expression of each probe set was determined rela-
tive to this geometric mean and 2log-transformed. The
geometric mean of the hybridization signal of all samples
was used to ascribe equal weight to gene expression levels
with similar relative distances to the geometric mean.
Next a query-by-example numerical query was performed
in OmniViz to find records most closely related to RAD21.
The top 25 genes that correlated the best with RAD21
were visualized using a treescape view.
Generation of stable RAD21 knockdown cell lines and
clonogenic survival assays
A single cell clone was derived from the human breast
cancer cell line, MDA-MB-231. This cell line is of the
basal subtype. Two different short-hairpin RNA
(shRNA) shRNAmir constructs, shRNA 57223 and
shRNA 57224, and shRNAmir vector control (Open Bio-
systems, Huntsville, AL, USA) were introduced into cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) and clones were selected following a two-week
culture in 2 μg/ml puromycin. Work involving recombi-
nant DNA was conducted in approved Physical Contain-
ment level 2 (PC2) facilities. Western blot analysis and
quantitative real-time PCR were used to verify the level
of RAD21 protein and mRNA.
Clonogenic survival was performed as described [21].
Exponentially growing cells were seeded in triplicate
plates, allowed to adhere for four to six hours. Following
24-hour incubation with individual drugs at graded con-
centrations, cells were cultured for two weeks. Surviving
colonies defined as containing more than 50 cells were
counted. Three independent experiments were per-
formed for each treatment. Survival curves were gener-
ated using the linear quadratic model, GraphPad Prism
version 5.01 for Windows, GraphPad Software, San
Diego, CA, USA.
Statistical analysis
Correlations were examined using the one-way
ANOVA, Students t-test, or chi-square test where
appropriate. Kaplan-Meier survival curves were calcu-
lated using tumor recurrence (relapse free survival)
and breast cancer-related death (overall survival) as
the endpoints and compared using a log rank test.
Binary logistic regression was used for multivariate
analyses and the Cox proportional hazard regression
model was used to identify independent prognostic
factors for disease-free and overall survival. Analyses
were performed with SPSS 16.0 (SPSS Inc., IL, USA).
A two-tailed P-value test was used in all analyses and
a P-value of less than 0.05 was considered statistically
significant.
Results
RAD21 protein expression in in situ and invasive breast
cancer
Expression of RAD21 in DCIS ranged from negative
(2/60 cases, 3%) to heterogenous staining (30/60 cases,
50%) and homogenous strong staining (28/60 cases,
47%) (Figure 1A). For invasive cancers, RAD21 staining
patterns were similar to DCIS, ranging from heteroge-
neous (50/95 cases, 53%) and homogeneous strong
staining (42/95 cases, 44%) to negative (3/95 cases, 3%)
(Figure 1B, C). No staining or minimal weak staining
was present in the cytoplasm in all cases. Expression
of RAD21 in invasive cancers was significantly lower
(104/343, 30%) than in in situ cancers (28/60, 47%)
(P = 0.001).
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Association between RAD21 expression and
clinicopathological characteristics in DCIS
RAD21 expression did not significantly associate with
nuclear grade (P = 0.428) (Table 1) or the intrinsic phe-
notypes in DCIS (P = 0.471) (Table 2). There was no
correlation between RAD21 expression in DCIS and risk
of relapse (P = 0.834).
Association between RAD21 expression and
clinicopathological characteristics and intrinsic subtypes
in invasive cancer
RAD21 expression correlated with larger tumor size
(P = 0.012) and lymph node involvement (P < 0.001),
but not with tumor grade (P = 0.328), age (P = 0.815),
HER2 status (P = 0.564) or ER status (P = 0.054)
(Table 3). Positive RAD21 expression was seen in 37%
(75/201) luminal, 24% (10/42) basal, 22% (9/49) HER2
and 18% (5/28) null, cancers. When compared to lumi-
nal cancers, null type cancers, but not basal and HER2
cancers, were significantly more likely to be RAD21
negative (P = 0.043) (Table 4).
RAD21 expression and its correlation with relapse-free
survival
There was a significant correlation between positive
RAD21 expression and shorter relapse-free survival (RFS)
(P = 0.009) (Figure 2A). The association with early relapse
was confirmed on multivariate analysis (P = 0.029, HR =
1.74, 95% CI 1.06 to 2.86) (Table 5). Subset analysis
revealed RAD21 expression correlated with relapse in
grade 3 (P = 0.023) (Figure 2B) but not in grade 1 or 2
tumors (P = 0.342) (Figure 2C). Further analysis of grade 3
tumors according to subtype showed a significant correla-
tion between RAD21 expression and shorter RFS in the
grade 3 luminal (P = 0.040) (Figure 2D), grade 3 basal (P =
0.018) (Figure 2E) and grade 3 HER2 cancers (P = 0.039)
(Figure 2F), but not null type cancers (P = 0.247).
RAD21 expression and its correlation with overall survival
in patients treated with chemotherapy
Among patients not treated with chemotherapy, there was
no correlation between RAD21 expression and overall sur-
vival (P = 0.779) (Figure 2G), whereas among patients
treated with chemotherapy there was a significantly
shorter overall survival in patients whose tumors were
positive for RAD21 expression (P = 0.020) (Figure 2H).
This association is also true for patients with grade 3
Figure 1 RAD21 immunohistochemistry in DCIS and invasive
carcinoma. A, Strong nuclear RAD21 staining in DCIS. Scale bar =
20 μm. B, Strong nuclear RAD21 staining in an invasive carcinoma,
luminal type. Scale bar = 20 μm. C, Absence of nuclear staining in
an invasive carcinoma, basal type. Scale bar = 20 μm.
Table 1 RAD21 expression by DCIS grade (P = 0.428)
Grade Negative
n (%)
Positive
n (%)
Total
n (%)
Low 3 (50.0%) 3 (50.0%) 6 (100.0%)
Intermediate 9 (60.0%) 6 (40.0%) 15 (100.0%)
High 8 (38.1%) 13 (61.9%) 21 (100.0%)
Total 20 (47.6%) 22 (52.4%) 42 (100.0%)
DCIS, ductal carcinoma in situ.
Table 2 RAD21 expression in DCIS subtypes (P = 0.471)
Subtype Negative
n (%)
Positive
n (%)
Total
n (%)
Luminal 21 (55.3%) 17 (44.7%) 38 (100%)
Basal 0 (.0%) 1 (100.0%) 1 (100%)
HER2 7 (43.8%) 9 (56.2%) 16 (100%)
Null 3 (75.0%) 1 (25.0%) 4 (100%)
Total 31 (52.5%) 28 (47.5%) 59 (100.0%)
DCIS, ductal carcinoma in situ.
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tumors (P = 0.021). No significant difference in overall
survival was seen in patients treated with endocrine ther-
apy, when stratified by RAD21 expression (P = 0.231).
RAD21 gene expression correlates with copy number
alterations, and RAD21 is amplified in a subset of grade 3
luminal, basal and HER2 cancers
In view of the correlation of RAD21 expression with
prognosis in grade 3 cancers, we examined RAD21
mRNA expression for its association with gene copy
number, in an integrated array CGH and transcriptional
dataset generated from 48 microdissected grade 3 inva-
sive ductal carcinomas of luminal (n = 22), basal-like (n
= 13) and HER2 (n = 13) subtypes [18]. Array CGH and
microarray expression profiling showed RAD21 mRNA
expression correlated with gene copy number in luminal
Table 3 RAD21 expression in invasive carcinoma by
clinicopathological parameters
negative
n (%)
positive
n (%)
Total
n (%)
P value
Grade P = 0.328
1 42 (17.6%) 16 (15.4%) 58 (16.9%)
2 96 (40.2%) 35 (33.7%) 131 (38.2%)
3 101 (42.3%) 53 (51.0%) 154 (44.9%)
Size P = 0.012
<20 mm 147 (61.8%) 50 (47.2) 197 (57.3%)
>20 mm 91 (38.2%) 56 (52.8%) 147 (42.7)
Lymph node P < 0.001
Negative 148 (63.5%) 43 (42.2%) 191 (57.0%)
Positive 85 (36.5%) 59 (57.8%) 144 (43.0%)
Age P = 0.815
<50 84 (35.1%) 39 (36.4%) 123 (35.5%)
>50 155 (64.9) 68 (63.6%) 223 (64.5%)
ER P = 0.054
Negative 63 (34.4%) 14 (21.5%) 77 (31/0%)
Positive 120 (65.6%) 51 (78.5%) 171 (69.0%)
HER2 P = 0.564
Negative 142 (79.8%) 54 (83.1%) 196 (80.7%)
Positive 36 (20.2%) 11 (16.9%) 47 (19.3%)
Chemotherapy* P = 0.032
No 117 (62.95) 31 (47.7%) 148 (59.0%)
Yes 69 (37.1%) 34 (52.3%) 103 (41.0%)
Endocrine therapy P = 0.034
No 97 (52.2%) 24 (36.9%) 121 (48.2%)
Yes 89 (47.8%) 41 (63.1%) 130 (51.8%)
* Chemotherapy was given either as cylcophosphamide/methotrexate/
fluorouracil (CMF), or doxorubicin (adriamycin)/cyclophosphamide (AC).
ER, oestrogen receptor.
Table 4 RAD21 expression in breast cancers by intrinsic
subtype
Subtype negative
n (%)
positive
n (%)
Total
n (%)
P-value
Relative to luminal
Luminal 126 (63%) 75 (37%) 201 (100%) -
Basal-like 32 (76%) 10 (24%) 42 (100%) 0.095
HER2 38 (78%) 11 (22%) 49 (100%) 0.050
Null 23 (82%) 5 (18%) 28 (100%) 0.043
Total 239 (70%) 104 (30%) 320 (100%)
Figure 2 Kaplan-Meier curves stratified by nuclear RAD21
expression, relapse-free survival (A-F) and overall survival (G-
H). Relapse free survival: A, in all tumors, (P = 0.009) (n = 247); B,
grade 3 cancers (P = 0.023) (n = 117); C, grade 1 and 2 cancers (P =
0.342) (n = 130); D, grade 3 luminal cancers (P = 0.040) (n = 32); E,
grade 3 basal cancers (P = 0.018) (n = 29); F, grade 3 HER2 cancers
(n = 34); Overall survival: G, without chemotherapy (P = 0.779) (n =
148). H, treated with chemotherapy (P = 0.020) (n = 91).
Table 5 Multivariate analysis, Cox regression model of
relapse-free survival in all breast cancers
P value Hazard Ratio 95% CI for hazard ratio
RAD21 0.029 1.74 1.06 to 2.86
Grade 0.018 1.63 1.09 to 2.44
Size > 20 mm 0.656 1.11 0.71 to 1.73
Lymph node status 0.023 1.69 1.07 to 2.65
ER 0.003 0.46 0.28 to 0.77
Age > 50 0.325 1.28 0.781 to 2.11
CI, confidence interval; ER, oestrogen receptor.
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(P = 0.003), basal (P = 0.0086) and HER2 (P = 0.0035)
tumors (Pearson correlation, Table 6). RAD21 amplifica-
tion is present in 32% (7/22) of luminal, 31% (4/13) of
basal and 22% (2/9) of HER2 subtypes. These propor-
tions were very similar to our immunohistochemistry
analysis of a different sample set described above, where
30% of luminal (14/46), 25% of basal (10/40), and 22%
of HER2 (9/41) grade 3 cancers showed positive RAD21
expression. Collectively, these data suggest that positive
RAD21 expression observed in a subset of grade 3
tumors may be due to gene amplification.
RAD21 expression in breast cancer cell lines
Variations in RAD21 protein expression in clinical
samples were reflected by gene expression analysis using
qRT-PCR of a panel of breast cancer cell lines (Figure 3A),
and by microarray profiling of 36 breast cancer cell lines
derived from Hollestelle et al. [19] (Figure 3B). Further
analysis revealed that TOP2A which encodes topoisome-
rase II (a protein also required for sister chromatid separa-
tion) and NIPBL (encoding a cohesin loading protein) are
among top 25 genes positively correlated with RAD21
expression (Figure 3B).
Knockdown of RAD21 gene expression with short-hairpin
RNA in a basal-like breast cancer cell line, MDA-MB-231,
results in its enhanced sensitivity to chemotherapeutic
drugs
To test the functional significance of our cancer therapy
results that RAD21 expression affects sensitivity to che-
motherapeutic drug response, we used a small hairpin
shRNA-mediated gene-silencing approach to knockdown
the RAD21 gene in MDA-MB-231 breast cancer cell
line. Of several independent cell clones generated using
two different shRNA constructs, three clones exhibited
a reduction in both RAD21 transcripts and protein
(Figure 4). The relative levels of RAD21 mRNA in four
stable clones, as determined by qRT-PCR analysis, were
56 ± 4% for sh223_sc1 (P = 0.010), 90 ± 13% for
sh223_sc3 (P = 0.531), 62 ± 13% for sh224_sc4 (P =
0.111) and 55 ± 2% for sh224_sc5 (P = 0.002), relative
to the parental cell line (Figure 4A). No apparent reduc-
tion in RAD21 mRNA was detected in the control clone
transfected with shRNAmir vector (96% ± 8%, P =
0.726) (Figure 4A). Further examination of the corre-
sponding RAD21 protein by semi-quantitative Western
blot analysis revealed a statistically significant reduction
in the levels of RAD21 protein in the three clones
(sh223_sc1, sh224_sc4 and sh224_sc5), which exhibited
RAD21 mRNA reduction (Figure 4A, B). The relative
levels of RAD21 protein were 82% ± 4% for sh223_sc1
(P = 0.017), 65 ± 4% for sh224_sc4 (P = 0.002) and 60 ±
6% for sh224_sc5 (P = 0.007), relative to the parental
cell line (Figure 4B). The RAD21 protein levels in the
Table 6 Correlation of RAD21 gene expression with
genomic alterations*
Subtype Copy number
Pearson
correlation
P-value
Gaina
Mann Whitney
U test
P-value
Amplificationb
Mann Whitney
U test
P-value
Luminal (n =
22)
0.0030 0.0169 0.0465
Basal-like (n
= 13)
0.0086 – 0.0111
HER2 (n = 13) 0.0035 0.0503 0.1025
* Patients and Methods were as described in Natrajan et al. (2009).
a Gain corresponds to approximately three to five copies of the locus as
defined using a smoothed Log2 ratio of between 0.08 and 0.45.
b Amplification was defined as having a Log2 ratio > 0.45, corresponding to
more than five copies.
CGH, comparative genomic hybridization.
Figure 3 Expression of RAD21 in breast cancer cell lines. A.
Quantitative real time RT-PCR of RAD21 transcripts in human breast
cancer cell lines. The expression level in MCF10A was used as a
reference and given an arbitary value of 1. Relative expression of
RAD21 gene was compared with MCF10A. Error bar = standard error
mean (SEM). B. OmniViz Treescape showing the hierarchical
clustering of the top 25 genes that correlated best with the two
RAD21 gene probes (200607_s_at and 200608_s_at). Gene
expression levels: red, up-regulation compared with the geometric
mean; green, down-regulation compared with the geometric mean.
The color intensity correlates with the degree of change. Raw
dataset (GEO:GSE16795) was sourced from GEO [20].
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sh224_sc4 and sh224_sc5 clones are comparable to that
in an immortalized human mammary epithelial cell line,
MCF10A (Figure 4B). No apparent reduction in RAD21
protein was detected in sh223_sc2 (99% ± 4%, P =
0.700), sh223_sc3 (97 ± 4%, P = 0.367) and shRNAmir
vector (101 ± 9%, P = 0.947), compared to the parental
line (Figure 4B). Thus, reduction of both RAD21 mRNA
and protein levels was confirmed in three stable
shRAD21 knockdown clones.
We next tested the response of shRAD21 clones to
two breast cancer chemotherapeutic drugs, cyclo-
phosphamide and 5-fluorouracil (5-FU). All three
RAD21 knockdown clones, sh223_sc1, sh224_sc4 and
sh224_sc5, showed increased sensitivity to the drug fol-
lowing treatment with cyclophosphamide, in a manner
that directly correlates with the level of RAD21 expres-
sion (Figure 5A). In contrast, such enhanced sensitivity
was not observed in the clone sh223_sc3 which did not
show a reduction in either RAD21 mRNA or protein
level (Figure 4). We noted that the sh223_sc1 clone
exhibited a more reduced clonogenic survival compared
to the other clones, sh224_sc4 and sh224_sc5. This may
be due to the difference in targeting sequences between
the sh223 and sh224 shRNAs. Similarly, treatment of
three shRAD21 clones (sh223_sc1, sh224_sc4 and
sh224_sc5) with 5-FU resulted in a significant reduction
in the clonogenic survival of all three clones compared
to the parental line (Figure 5B). These data recapitulate
our findings in patients treated with cyclophosphamide/
methotrexate/5-fluorouracil (CMF) or doxorubicin
(adriamycin)/cyclophosphamide (AC) (Figure 2H), pro-
viding further evidence that RAD21 expression corre-
lates with cellular sensitivity to chemotherapeutic-drugs.
Since our analysis showed that RAD21 expression
strongly correlates with TOP2A expression in a number
of breast cancer cell lines (see Figure 3), we assessed
the sensitivity of RAD21 knockdown clones to etoposide,
a topoisomerase II inhibitor and commonly used anti-c-
ancer drug. Etoposide treatment also led to a marked
decrease in cell survival in the shRAD21 clones tested,
compared to the parental cells (Figure 5C). This result
is consistent with an early report of an enhanced etopo-
side-sensitivity following a siRNA-mediated transient
RAD21 knockdown in MCF7 breast cancer cell line [10].
Discussion
This translational study is the first comprehensive analy-
sis of a novel chromosomal DNA repair protein, RAD21
cohesin, in breast cancer. Our analyses provide compel-
ling evidence that RAD21 expression is a novel prognos-
tic marker in breast cancer and is also highly predictive
of anti-cancer therapy outcomes. Tumor RAD21 overex-
pression strongly correlated with amplification of the
RAD21 gene locus in a significant subset of high grade
luminal, basal and HER2 cancers. This suggests that the
observed RAD21 overexpression resulted from gene
amplification, and provides a plausible explanation for
the strong RAD21 prognostic effects observed in these
tumors. Our findings in breast cancer with the RAD21
cohesin may also generalize to some other epithelial
Figure 4 Validation of RAD21 expression in MDA-MB-231 cells
carrying shRAD21 knockdown constructs. A. Quantitative real
time PCR analysis of RAD21 expression in clones stably expressing
two different shRAD21 constructs and shRNAmir vector, relative to
the parental cell line. B. Western blot analysis of RAD21 protein
level. RAD21 expression in five independently derived clonal cell
lines with two different stable RAD21 knockdown constructs was
compared to the parental cell line, cells transfected with shRNAmir
vector and an immortalized human breast epithelial cell line
MCF10A. Pan-actin was used as loading control. A reduction in the
levels of RAD21 protein in three stable clones (sh223_sc1, sh224_sc4
and sh224_sc5) was verified by semi-quantitative Western blot
analysis (bottom panel). The levels of RAD21 protein were
normalized to the pan-actin loading control and expressed as the
percentage of the parental line where the RAD21 expression was
given an arbitrary value of 100%. The values represent the mean of
four independent experiments except for shRNAmir vector and
MCF10A where three independent experiments were performed.
Clones with a significant reduction in either RAD21 mRNA or protein
levels were marked by asterisks (* P < 0.05; ** P < 0.005, Student t-
test). Error bar = SEM.
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cancer types: consistent with our data, RAD21 at chro-
mosomal locus 8q24 is also commonly amplified in
advanced androgen-resistant prostate cancer [11].
Our immunohistochemical analysis showed that
RAD21 expression associates with shorter relapse-free
survival in patients with high grade breast cancer.
Based on known RAD21 functions, the adverse out-
come in breast cancer patients with RAD21 expression
could be due to an elevated level of homologous
recombination (HR) repair activity as a result of
RAD21 overexpression. We favor this explanation.
Overexpression of other HR proteins (for example,
RAD51, BRCA1) has also been shown to be associated
with increased resistance to radio- and chemo-therapy
[22,23]. Furthermore, should RAD21 expression prove
to be a surrogate for HR activity, this may provide a
simple, cost-effective and novel way for evaluating HR
activity on tissue sections. Alternatively, numerical
chromosome (ploidy) alterations as a result of chromo-
some segregation errors could contribute to the poorer
survival outcomes we observed.
RAD21 expression is a prognostic and predictive fac-
tor that affects the ultimate outcome in many breast
cancer sub-histotypes. Prior to clinical use, these data
will require validation, for example, in another (larger)
clinical dataset, including assessment in a randomised
clinical trial. Once validated, RAD21 expression would
have potential translational use in the clinical manage-
ment of patients. Immunohistochemical evaluation of
RAD21 protein on breast cancer specimens could be
routinely incorporated into standard pathology reporting
to estimate levels of RAD21 that might determine drug
response of certain drug regimens.
Furthermore, our survival analysis revealed that in
patients receiving chemotherapy, those patients with
tumors positive for RAD21 expression showed a signifi-
cantly shorter overall survival than patients whose tumors
were negative for RAD21, highlighting an exciting poten-
tial role for RAD21 expression in predicting cancer ther-
apy response. We further verified the relevance of
RAD21 expression to the therapeutic response in vitro.
Stable knockdown of RAD21 significantly enhanced, in a
graded fashion, cellular sensitivity to 5-FU, cyclophospha-
mide and etoposide. The first two of these drugs are
components of the commonly used FEC (5-FU/epirubi-
cin/cyclophosphamide), CMF (cyclophosphamide/metho-
trexate/5-fluorouracil) and AC (doxorubicin (adriamycin)/
cyclophosphamide) regimens for breast cancer. The
repair of DNA adducts caused by 5-FU, cyclophospha-
mide and etoposide depends on HR [24-26] although this
dependency on HR is only partial for the repair of cyclo-
phosphamide-induced DNA interstrand crosslinks [27].
The decrease in cell survival that correlated with levels of
RAD21 in breast cancer cells after RAD21 knockdown, is,
therefore, in keeping with the dependence of breast can-
cer cells on the HR pathway to repair DNA damage from
chemotherapy [10]. Consistent with this proposition, we
noted that both topoisomerase II and the RAD21 loading
protein NIPBL, showed strong coordinately regulated
expression with RAD21 in breast cancer cell lines.
RAD21 is recruited, in a manner dependent on the cohe-
sin loading protein NIPBL, to the sites of DNA double
strand breaks such as those generated by topoisomerase
II, promoting DNA repair in human cells [28]. Further,
topoisomerase II also decatenates chromosomes before
the condensation needed for RAD21 cohesin-mediated
chromosome segregation. Collectively, ours and other
data highlight the likely effects of the DNA repair func-
tions of RAD21 in tumor biology, and their potential
importance in cancer treatment, although other aberrant
Figure 5 Effect of shRNA-mediated RAD21 knockdown on
cellular sensitivity to anti-cancer drugs. Independent cell clones
with stably reduced RAD21 expression were derived from the breast
cancer cell line, MDA-MB-231. Relative levels of RAD21 gene
expression when compared to the parental line by qRT-PCR and
semi-quantitative Western blot analysis were shown in Figure 4.
Error bar = SEM. Clonogenic survival following treatment with: A.
cyclophosphamide: sh223_sc1 (P = 0.0316), sh223_sc3 (P = 0.175),
sh224_sc4 (P = 0.0187) and sh224_sc5 (P = 0.0563); B. 5-FU:
sh223_sc1 (P = 0.020), sh224_sc4 (P = 0.0257) and sh224_sc5 (P =
0.0242); and C. etoposide: sh223_sc1 (P = 0.020) and sh224_sc5 (P =
0.042).
Xu et al. Breast Cancer Research 2011, 13:R9
http://breast-cancer-research.com/content/13/1/R9
Page 8 of 10
functions of RAD21 could theoretically contribute to our
observed associations and phenotypes.
In conclusion, the predictive function of RAD21
expression for chemotherapy outcome suggests that
RAD21 expression could be used to guide treatment
selection. For example, in high grade tumors with
enhanced RAD21 expression, consideration could be
given to using chemotherapeutic drugs that are inhibi-
tors of HR repair [25]. Furthermore, it could guide the
use of alternative strategies, such as drug dosage intensi-
fication, other chemotherapy drugs with activity in
breast cancer, or chemotherapy in combination with
radiotherapy (RT) which is a potent inducer of DNA
double stand breaks. Further testing of the sensitivity of
RAD21 knockdown clones to other chemotherapeutic
agents may be of utility. Because of its effect on prog-
nosis and therapeutic outcome, enhanced RAD21
expression may also be a novel therapeutic target. Many
of the methodologies used to clinically counteract onco-
gene expression, (for example, gene therapy, antisense
oligonucleotide therapy, specific microRNA expression),
could be entertained to reduce RAD21 levels.
Conclusions
In summary, expression of RAD21 in a significant subset
of breast cancers confers poor prognosis in high grade
luminal, basal and HER2 breast cancers, and resistance
to chemotherapy in breast cancer. RAD21 may be a
novel marker of poor prognosis, a predictive factor for
systemic therapy outcomes and a new target for breast
cancer therapy.
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